OBJECTIVE: To evaluate the clinical outcomes in patients with cancer of an unknown primary site (CUP), who were treated by gastrointestinal oncologists. METHODS: We retrospectively studied 29 patients with CUP who were presented at the Department of Gastroenterology, Kitasato University Hospital from October 2005 to October 2013, and were treated by the gastrointestinal oncologists. The patients were divided into two groups, namely chemotherapy group and symptomatic therapy group, and the clinical characteristics and survival times were compared. The clinical course was studied according to the histologic type (adenocarcinoma or non-adenocarcinoma), prognostic subset (favorable or unfavorable), and the presence or absence of chemotherapy. RESULTS: The chemotherapy group comprised 19 patients, and the symptomatic therapy group comprised 10 patients. The median survival time was 11 months in the chemotherapy group and 3 months in the symptomatic therapy group. Twenty-two patients had adenocarcinoma, and 7 had non-adenocarcinoma. Of the 22 patients with adenocarcinoma, 2 belonged to the favorable prognostic subset and received chemotherapy. One of these patients died of cancer at 47 months, and the other was alive and disease free at 58 months. Among the 20 patients with adenocarcinoma in the unfavorable prognostic subset, 16 received chemotherapy and had a median survival of 16 months. Seven (44%) of these patients survived for at least 21 months, and 3 patients who could receive 3 or more regimens survived for at least 46 months. CONCLUSION: It might be appropriate for gastrointestinal oncologists to treat CUP on the basis of clinical experience, depending on the situation.
OBJECTIVE: To evaluate the clinical outcomes in patients with cancer of an unknown primary site (CUP), who were treated by gastrointestinal oncologists. METHODS: We retrospectively studied 29 patients with CUP who were presented at the Department of Gastroenterology, Kitasato University Hospital from October 2005 to October 2013, and were treated by the gastrointestinal oncologists. The patients were divided into two groups, namely chemotherapy group and symptomatic therapy group, and the clinical characteristics and survival times were compared. The clinical course was studied according to the histologic type (adenocarcinoma or non-adenocarcinoma), prognostic subset (favorable or unfavorable), and the presence or absence of chemotherapy. RESULTS: The chemotherapy group comprised 19 patients, and the symptomatic therapy group comprised 10 patients. The median survival time was 11 months in the chemotherapy group and 3 months in the symptomatic therapy group. Twenty-two patients had adenocarcinoma, and 7 had non-adenocarcinoma. Of the 22 patients with adenocarcinoma, 2 belonged to the favorable prognostic subset and received chemotherapy. One of these patients died of cancer at 47 months, and the other was alive and disease free at 58 months. Among the 20 patients with adenocarcinoma in the unfavorable prognostic subset, 16 received chemotherapy and had a median survival of 16 months. Seven (44%) of these patients survived for at least 21 months, and 3 patients who could receive 3 or more regimens survived for at least 46 months. CONCLUSION: It might be appropriate for gastrointestinal oncologists to treat CUP on the basis of clinical experience, depending on the situation.
Entities:
Keywords:
adenocarcinoma; cancer of an unknown primary site; chemotherapy; favorable subset; gastrointestinal oncologist; unfavorable subset
Authors: J D Hainsworth; H A Burris; S W Calvert; N T Willcutt; D C Scullin; J Bramham; F A Greco Journal: Cancer Invest Date: 2001 Impact factor: 2.176
Authors: Eric Yaovi Amela; Géraldine Lauridant-Philippin; Sophie Cousin; Thomas Ryckewaert; Antoine Adenis; Nicolas Penel Journal: Crit Rev Oncol Hematol Date: 2012-04-11 Impact factor: 6.312
Authors: F Anthony Greco; Howard A Burris; Sharlene Litchy; John H Barton; James E Bradof; Paul Richards; Daniel C Scullin; Joan B Erland; Lisa H Morrissey; John D Hainsworth Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Bryan J Schneider; Basil El-Rayes; Jeffery H Muler; Philip A Philip; Gregory P Kalemkerian; Kent A Griffith; Mark M Zalupski Journal: Cancer Date: 2007-08-15 Impact factor: 6.860